Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224874 · ClinicalTrials.gov registry record · Phase 2
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
A Phase 2 study of Graft Vs Host Disease and Immune System Disorders, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 19
- Study locations
NCT00224874: Completed Phase 2 study of Graft Vs Host Disease and Immune System Disorders, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00224874 is a Phase 2 study of Graft Vs Host Disease and Immune System Disorders that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 180 participants, above the 133-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (35% higher). The trial reports 19 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00224874, a Phase 2 study of Graft Vs Host Disease and Immune System Disorders, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 19
- Study locations
Study Summary
The study is a randomized Phase II, four arm treatment trial. The primary purpose of the study is to define new agents with promising activity against acute graft-versus-host disease (GVHD) suitable for testing against corticosteroids alone in a subsequent Phase III trial.
Primary Outcome
Complete response at day 28 after randomization. CR was defined as resolution of all signs and symptoms of Graft-Versus-Host Disease (GVHD) in all evaluable organs in comparison to Day 1 scoring.
Conditions Studied
Interventions
- DRUG Mycophenolate Mofetil
- DRUG Pentostatin
- DRUG Etanercept
- DRUG Denileukin Diftitox
Study Locations (19)
California
- City of Hope National Medical Center - Duarte
- University of California - San Diego
- Stanford Hospital and Clinics - Stanford
Texas
- University of Texas/MD Anderson CRC - Houston
- Texas Transplant Institute - San Antonio
Florida
- University of Florida College of Medicine (Shands) - Gainesville
Maryland
- Johns Hopkins/SKCCC - Baltimore
Massachusetts
- DFCI/Brigham & Women's Hospital - Boston
Michigan
- University of Michigan Medical Center - Ann Arbor
Minnesota
- University of Minnesota - Minneapolis
Missouri
- Washington University/Barnes Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2005-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
What the finished NCT00224874 record still lists
NCT00224874 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (35% higher).
The record links to 2 conditions, with Graft Vs Host Disease appearing as the primary indexed condition, and to 4 interventions - of which Mycophenolate Mofetil is the first listed.
NCT00224874 lists 19 locations in 16 states (California, Texas, Florida).
Frequently Asked Questions
What is clinical trial NCT00224874 about?
NCT00224874 is a clinical study titled "Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)". The study is a randomized Phase II, four arm treatment trial. The primary purpose of the study is to define new agents with promising activity against acute graft-versus-host disease (GVHD) suitable for testing against corticosteroids alone in a subsequent Phase III trial.
What is the current status of trial NCT00224874?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2005-09. Estimated completion is 2012-06.
What conditions does trial NCT00224874 study?
This clinical trial studies the following conditions: Graft Vs Host Disease, Immune System Disorders.
What interventions are being tested in trial NCT00224874?
The interventions under investigation include: Mycophenolate Mofetil (DRUG), Pentostatin (DRUG), Etanercept (DRUG), Denileukin Diftitox (DRUG).
Who is sponsoring clinical trial NCT00224874?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00224874 being conducted?
This trial has 19 study locations across California, Florida, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00224874's enrollment target sits among peer trials
180 8th of 36 higher than 29 of 36 other Graft Vs Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft Vs Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
-
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
RECRUITING · Phase 2
-
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
ACTIVE NOT RECRUITING · Phase 2
-
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
ACTIVE NOT RECRUITING · Phase 2
-
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia